MedTrace Logo

Prognostic Value of "CD200" in Hematological Malignancies. Hematological Malignancies Comprise a Group of Malignant Clonal Disorders Arising From the Hematopoietic Tissues , Including Leukemia , Multiple Myeloma , and They Have a High Morbidity and Mortality

NCT06258629 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2024-02-14

No results posted yet for this study

Summary

Prognostic value of 'CD200' in hematological malignancies Hematological malignancies comprise a group of malignant clonal disorders arising from the hematopoietic tissues , including leukemia , multiple myeloma , and lymphoma , and they have a high morbidity and mortality

Conditions

Interventions

DIAGNOSTIC_TEST

Flowcytometry on bone marrow aspiration

Flowcytometry on bone marrow aspiration

Sponsors & Collaborators

  • Sohag University

    lead OTHER

Eligibility

Min Age
1 Year
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-02-15
Primary Completion
2025-02-06
Completion
2025-02-06

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06258629 on ClinicalTrials.gov